Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. (NASDAQ: NEO) is a cancer diagnostics company focused on oncology genetics testing and information services. This news page aggregates company announcements, conference presentations, financial updates, and other disclosures that relate to NeoGenomics’ role in precision oncology and testing laboratories.
Readers can find earnings and financial news, including quarterly and preliminary full-year revenue updates furnished through press releases and Form 8-K filings. These items describe trends in clinical test volumes, next-generation sequencing (NGS) revenue, and other aspects of the company’s oncology testing business.
The news feed also features scientific and clinical research updates. NeoGenomics regularly announces data presentations at major oncology and hematology meetings, such as the San Antonio Breast Cancer Symposium, the American Society of Hematology Annual Meeting, the International Society of Liquid Biopsy Annual Congress, and the European Society for Medical Oncology Congress. These updates often highlight molecular residual disease (MRD) studies using RaDaR assays, comprehensive genomic profiling in myeloid malignancies, and liquid biopsy-based genomic profiling across solid tumors.
In addition, investors and clinicians can follow corporate and governance developments, including board appointments, executive transitions, and participation in investor conferences. Together, these news items provide a view into how NeoGenomics advances its oncology diagnostics platforms, supports pharmaceutical partners and academic collaborators, and manages its public-company responsibilities. For ongoing insight into NEO stock-related developments and oncology testing initiatives, this page serves as a centralized news resource.
NeoGenomics (NASDAQ: NEO) and Elevation Oncology announced a collaboration to improve the identification of patients with solid tumors that have NRG1 gene fusions. This partnership aims to enroll eligible patients in the Phase 2 CRESTONE study, targeting the treatment of these rare genetic alterations. NRG1 fusions are found in approximately 0.2% of solid tumors and are actionable targets for precision oncology. The collaboration reflects a commitment to enhance diagnostic capabilities and patient outcomes in oncology.
NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 10:50 AM ET. CFO Kathryn McKenzie and Chief Strategy Officer Doug Brown will discuss the company's cancer-focused genetic testing services. The presentation will be available via webcast on the company's website. NeoGenomics specializes in oncology testing and supports pharmaceutical clients in clinical trials. The company operates multiple accredited laboratories across the U.S. and internationally.
NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 10:00 AM ET. Key executives, including CEO Douglas VanOort and CFO Kathryn McKenzie, will be involved in the presentation. The event will be webcast live, accessible via the company’s investor relations page. NeoGenomics specializes in cancer genetic testing and serves a wide range of healthcare providers and pharmaceutical firms globally. For more information, visit www.neogenomics.com.
NeoGenomics reported a record revenue of $126 million for Q4 2020, an 18% increase year-over-year. Clinical Services revenue rose 14% to $107 million, boosted by $9 million in COVID-19 testing. Pharma Services revenue surged 43% to $19 million with a backlog growth of 60% to $209 million. Although net income for 2020 declined to $4 million from $8 million in 2019, adjusted EBITDA fell to $35 million from $57 million. The company completed stock and convertible note offerings, generating $553 million for corporate growth and acquisitions.
NeoGenomics, Inc. announces a leadership transition with Mark Mallon set to become CEO on April 19, 2021, succeeding Douglas M. VanOort, who will assume the role of executive chairman. VanOort, who led the company for 12 years, helped grow revenues from $20 million to approximately $500 million, and increased market capitalization from $26 million to over $6 billion. Mallon, previously CEO of Ironwood Pharmaceuticals, brings extensive experience from AstraZeneca. The change aims to build on NeoGenomics' strong competitive position in oncology testing and enhance value for stakeholders.
NeoGenomics, Inc. (NASDAQ:NEO) will participate in the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference on February 19, 2021 at 9:30am ET. Presenters include CEO Douglas VanOort, CFO Kathryn McKenzie, and Chief Strategy Officer Doug Brown. The event will be available via live webcast on the company's investor relations website. NeoGenomics specializes in cancer genetics testing and provides comprehensive services for diagnostics and drug development for various healthcare entities worldwide.
NeoGenomics, Inc. (NASDAQ:NEO) announced plans to release its fourth quarter and full year 2020 financial results on February 24, 2021. A conference call to discuss these results is scheduled for 8:30 AM EDT on the same day. Investors can access the call by dialing the provided numbers. NeoGenomics specializes in cancer genetics testing and offers comprehensive oncology-focused testing services. The Company operates accredited laboratories across the U.S., Switzerland, and Singapore, serving a variety of healthcare entities.
Parexel and NeoGenomics have announced a strategic partnership aimed at enhancing oncology clinical trials through the application of real-world genomic data. This collaboration will facilitate better patient matching and optimize trial design by identifying genomic mutations and linking patient data with clinical datasets. The partnership seeks to accelerate patient enrollment in clinical trials and improve treatment outcomes. Both companies aim to expand their relationship in the oncology space by exploring advancements in lab services and biomarker capabilities.
The Access to Comprehensive Genomic Profiling Coalition has welcomed NeoGenomics (NASDAQ: NEO) and Tempus, emphasizing advocacy for broad U.S. insurance coverage of comprehensive genomic profiling (CGP) for advanced cancer patients. NeoGenomics offers extensive cancer diagnostics and services, while Tempus utilizes AI to enhance precision medicine efforts. Both companies aim to improve patient outcomes through better access to CGP, which informs treatment decisions. The coalition will also engage insurers to highlight the clinical and economic benefits of CGP.
NeoGenomics announced the pricing of public offerings of 4,081,632 shares of common stock at $49.00 per share, aiming for gross proceeds of $200 million, and $300 million in 0.25% convertible senior notes due 2028. The offerings are set to close around January 11, 2021. The convertible notes have an initial conversion price of approximately $66.15 per share, with a conversion premium of 35%. Proceeds will be utilized for general corporate purposes and potential investments. Underwriters have a 30-day option to purchase additional shares and notes.